FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003357158> ?p ?o ?g. }

• W2003357158 endingPage "115" @default.
• W2003357158 startingPage "109" @default.
• W2003357158 abstract "Primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) has been shown to be the preferred reperfusion strategy. Adjunctive GP IIb/IIIa inhibitors improve the outcome in patients with ST-elevation myocardial infarction undergoing primary percutaneous intervention (PCI). Intracoronary (IC) GP IIb/IIIa bolus application results in high local drug concentrations and may be more effective than a standard intravenous bolus. It remains unclear which of the two available GP IIb/IIIa inhibitors in Egypt eptifibatide and tirofiban would be of great benefit when used as IC bolus. Sixty patients with anterior STEMI undergoing primary PCI in Ain Shams University Hospitals were randomized to either intracoronary eptifibatide (Integrilin®) double bolus dose (n = 30) or IC tirofiban (Aggrastat®) high bolus dose (n = 30) with subsequent 12–24 h intravenous infusion of the same GP IIb/IIIa inhibitors. The primary end point was achievement of TIMI III flow and at least MBG II or III. The secondary end points were in hospital occurrence of major adverse cardiac events (MACE) including death, recurrent ischemia and target vessel revascularization, successful ST segment resolution and preservation of systolic function. The safety endpoint was in hospital occurrence of any major or minor bleeding according to TIMI classification. All baseline characteristics including demographics, risk factors, clinical data, time of chest pain, basic ECG data and angiographic data were statistically nonsignificant among both study groups. Regarding primary endpoint: No statistically significant difference in achievement of TIMI III flow, but achievement of MBG II and III indicating successful perfusion was much higher in eptifibatide group (76.6%) than tirofiban group (36.6%) p = 0.005. Regarding secondary end points: No statistically significant difference in rate of in-hospital MACE among both groups with one death (3.3%) in each group, but less recurrent ischemia in eptifibatide group (0%) than tirofiban group (16.7%) p = 0.026., also successful ST segment resolution as indirect sign of successful reperfusion (70.9 ± 11.3 versus 59.7 ± 9) and systolic function preservation (EF of 46.6 ± 5.5 versus 39.9 ± 6) were significantly better in eptifibatide group p < 0.001. Regarding safety end points: There was no difference in TIMI major bleeding among both groups but TIMI minor bleeding had occurred in tirofiban group (33.3%) more than eptifibatide group (0%) p < 0.001. In patient with anterior STEMI treated by primary PCI IC eptifibatide was superior to IC tirofiban in terms of successful perfusion, less recurrent ischemia, more ST segment resolution, and systolic function preservation with less TIMI minor bleeding." @default.
• W2003357158 created "2016-06-24" @default.
• W2003357158 creator A5025740140 @default.
• W2003357158 creator A5032336874 @default.
• W2003357158 creator A5046334872 @default.
• W2003357158 creator A5055059687 @default.
• W2003357158 creator A5083193101 @default.
• W2003357158 date "2011-06-01" @default.
• W2003357158 modified "2023-10-09" @default.
• W2003357158 title "Comparison between the effect of intracoronary bolus of tirofiban versus eptifibatide as adjunctive antiplatelet therapy on the outcome of primary coronary intervention in patients with acute anterior ST segment elevation myocardial infarction" @default.
• W2003357158 cites W1435359176 @default.
• W2003357158 cites W1974718993 @default.
• W2003357158 cites W1983567586 @default.
• W2003357158 cites W2002429810 @default.
• W2003357158 cites W2021926698 @default.
• W2003357158 cites W2037244319 @default.
• W2003357158 cites W2041039863 @default.
• W2003357158 cites W2054075375 @default.
• W2003357158 cites W2059215195 @default.
• W2003357158 cites W2086437366 @default.
• W2003357158 cites W2095897917 @default.
• W2003357158 cites W2109027426 @default.
• W2003357158 cites W2114140664 @default.
• W2003357158 cites W2132921310 @default.
• W2003357158 cites W2134741080 @default.
• W2003357158 cites W2144829626 @default.
• W2003357158 cites W2145232174 @default.
• W2003357158 cites W2147615829 @default.
• W2003357158 cites W2147629768 @default.
• W2003357158 cites W2157239643 @default.
• W2003357158 cites W2160926874 @default.
• W2003357158 cites W2162362068 @default.
• W2003357158 cites W2232858378 @default.
• W2003357158 cites W2281862598 @default.
• W2003357158 cites W2333133657 @default.
• W2003357158 cites W2887768525 @default.
• W2003357158 cites W4235858444 @default.
• W2003357158 cites W4254730674 @default.
• W2003357158 doi "https://doi.org/10.1016/j.ehj.2011.09.002" @default.
• W2003357158 hasPublicationYear "2011" @default.
• W2003357158 type Work @default.
• W2003357158 sameAs 2003357158 @default.
• W2003357158 citedByCount "0" @default.
• W2003357158 crossrefType "journal-article" @default.
• W2003357158 hasAuthorship W2003357158A5025740140 @default.
• W2003357158 hasAuthorship W2003357158A5032336874 @default.
• W2003357158 hasAuthorship W2003357158A5046334872 @default.
• W2003357158 hasAuthorship W2003357158A5055059687 @default.
• W2003357158 hasAuthorship W2003357158A5083193101 @default.
• W2003357158 hasBestOaLocation W20033571581 @default.
• W2003357158 hasConcept C126322002 @default.
• W2003357158 hasConcept C164705383 @default.
• W2003357158 hasConcept C168563851 @default.
• W2003357158 hasConcept C203092338 @default.
• W2003357158 hasConcept C2776335557 @default.
• W2003357158 hasConcept C2777871224 @default.
• W2003357158 hasConcept C2777995511 @default.
• W2003357158 hasConcept C2780400711 @default.
• W2003357158 hasConcept C2780739214 @default.
• W2003357158 hasConcept C2781056559 @default.
• W2003357158 hasConcept C42219234 @default.
• W2003357158 hasConcept C43376680 @default.
• W2003357158 hasConcept C45393284 @default.
• W2003357158 hasConcept C500558357 @default.
• W2003357158 hasConcept C71924100 @default.
• W2003357158 hasConceptScore W2003357158C126322002 @default.
• W2003357158 hasConceptScore W2003357158C164705383 @default.
• W2003357158 hasConceptScore W2003357158C168563851 @default.
• W2003357158 hasConceptScore W2003357158C203092338 @default.
• W2003357158 hasConceptScore W2003357158C2776335557 @default.
• W2003357158 hasConceptScore W2003357158C2777871224 @default.
• W2003357158 hasConceptScore W2003357158C2777995511 @default.
• W2003357158 hasConceptScore W2003357158C2780400711 @default.
• W2003357158 hasConceptScore W2003357158C2780739214 @default.
• W2003357158 hasConceptScore W2003357158C2781056559 @default.
• W2003357158 hasConceptScore W2003357158C42219234 @default.
• W2003357158 hasConceptScore W2003357158C43376680 @default.
• W2003357158 hasConceptScore W2003357158C45393284 @default.
• W2003357158 hasConceptScore W2003357158C500558357 @default.
• W2003357158 hasConceptScore W2003357158C71924100 @default.
• W2003357158 hasIssue "2" @default.
• W2003357158 hasLocation W20033571581 @default.
• W2003357158 hasLocation W20033571582 @default.
• W2003357158 hasOpenAccess W2003357158 @default.
• W2003357158 hasPrimaryLocation W20033571581 @default.
• W2003357158 hasRelatedWork W103736013 @default.
• W2003357158 hasRelatedWork W2033666660 @default.
• W2003357158 hasRelatedWork W2163292105 @default.
• W2003357158 hasRelatedWork W2371995401 @default.
• W2003357158 hasRelatedWork W2380861129 @default.
• W2003357158 hasRelatedWork W2384924065 @default.
• W2003357158 hasRelatedWork W2385764678 @default.
• W2003357158 hasRelatedWork W2391976880 @default.
• W2003357158 hasRelatedWork W2393113979 @default.
• W2003357158 hasRelatedWork W2740454508 @default.
• W2003357158 hasVolume "63" @default.
• W2003357158 isParatext "false" @default.
• W2003357158 isRetracted "false" @default.

• next